Palvella Therapeutics announced FDA acceptance and priority review of its NDA for QTORIN™ rapamycin to treat microcystic lymphatic malformations, a rare disease affecting over 30,000 in the U.S. The FDA's target decision date is February 28, 2027. Palvella is preparing for a potential U.S. commercial launch in early 2027 and advancing multiple other QTORIN™ programs for rare skin diseases. The company reported $236.7 million in cash and investments as of September 30, 2026, supporting ongoing development and commercialization efforts.
Palvella Therapeutics' recent corporate update and financial results provide context for readers. For those following the health sector, 94 of 150 priced US health stocks on Pluang rose while 48 fell. Notable movers include ALMS at USD 6.20 with a -5.34% change, OSCR at USD 36.95 with a +5.00% change and 59% buy order activity, and ADPT at USD 27.99 with a +4.79% change and 100% buy order activity. This data is as of Nov 05, 2026 19:01 WIB.
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
ACM Research reported a 37% year-over-year revenue increase to $367.7 million in Q3 2026, driven by strong demand in electrochemical plating (ECP) and advanced packaging technologies. The company is expanding manufacturing capacity and global sales e...
Purple has renewed its partnership with Lucid Motors to continue providing WiFi services across Lucid's operations in Riyadh. This renewal ensures that both staff and visitors have secure and easy internet access, supporting Lucid's growing presence ...
Investec Bank Plc, acting as joint broker to SThree Plc, disclosed public dealings involving the purchase and sale of 118,333 ordinary shares each on November 4, 2026. The transactions were conducted within a price range of 295 to 304 per share. Ther...
